Swedish BioFINDER 2 Study to Improve Early Diagnosis and Understanding of Dementia and Parkinsonian Disorders Using Advanced Imaging and Biomarkers in Adults Aged 20 to 100 Years

What this Trial Is About

Researchers are investigating dementia and related neurodegenerative diseases, including Alzheimers disease, Parkinsons disease, and other dementias, through the Swedish BioFINDER 2 Study. Building on the earlier BioFINDER 1 study, this research aims to improve early and accurate diagnosis using advanced imaging and biomarker techniques. The study also seeks to understand disease mechanisms, develop pathology-based classifications, and monitor the effects of new therapies in people with different stages of cognitive impairment and dementia. The study involves multiple participant groups ranging from cognitively healthy younger adults to patients with mild cognitive impairment or dementia due to Alzheimers and other neurodegenerative diseases. Participants undergo brain imaging including PET scans for amyloid and tau proteins, MRI, and DaTSCAN for certain parkinsonian disorders. Biomarker analyses are conducted from cerebrospinal fluid and blood samples. Follow-up assessments occur regularly over periods from 2 to 8 years depending on the cohort, with repeated cognitive, neurological, psychiatric, motor function tests, and imaging at defined intervals. During the study, participants complete detailed cognitive testing, motor assessments, and questionnaires addressing memory, attention, behavioral symptoms, mood, quality of life, and sleep. Clinical diagnoses and cognitive decline are monitored annually or biennially. Safety and adherence are ensured by standardized sampling protocols and imaging procedures. The main outcomes include clinical diagnosis, dementia rating scales, and biomarker changes, supporting improved diagnosis and understanding of dementia progression in diverse populations.

The Swedish BioFINDER 2 Study